The UK government has a six-month window to decide on a more than $400 million deal between the National Health Service (NHS) and American software firm Palantir, a decision amplified by Greater Manchester's healthcare board, the only region to reject the company's data platform.
The NHS commissioned Palantir in 2023 to build a "federated data platform" (FDP) aimed at consolidating the nation's health data. Palantir and the NHS claim the system is already improving patient wait times, hospital stays, and operating theatre efficiency. However, the deal has become a focal point of controversy in the UK, sparking protests and parliamentary inquiries, partly due to Palantir's involvement in military operations and US immigration enforcement.
Greater Manchester's healthcare board has consistently opted out of Palantir's FDP, preferring a homegrown platform developed over ten years. They argue their existing system is superior and enjoys greater public trust. Matt Hennessey, chief data and analytics officer at NHS Greater Manchester, stated that even a technically strong platform struggles without user confidence, and adopting the FDP would be a "retrograde step." This stance, contested by Palantir and FDP supporters, fuels the national debate about whether the government should terminate the contract early next February instead of letting it run until 2031.
Historically, the NHS has grappled with fragmented patient records across various digital systems, spreadsheets, and paper, leading to potential risks and inefficient resource allocation. Palantir's FDP was designed to unify this data, creating a national pool for identifying care gaps and local databases for region-specific analyses. Tom Bartlett, an independent IT consultant who previously worked on the FDP rollout, highlighted its "lift and shift" capability and its potential as a surface for AI applications.
While 139 out of approximately 200 NHS trusts and 35 out of 36 Integrated Care Boards (ICBs) are reportedly using Palantir's technology, some regional trusts, including those in Greater Manchester, are said to be using it only for limited purposes. Andy Haywood of Health Innovation Manchester suggested that some organizations are merely logging usage without full data integration. Greater Manchester ICB, however, has categorically refused to adopt the FDP, maintaining that its own Analytics and Data Science Platform (ADSP) offers superior functionality and flexibility, with some features reportedly three years ahead of the FDP. Hennessey also emphasized the deep public trust fostered by the ADSP, crucial for gathering sensitive health data.
Palantir disputes claims of the ADSP's superiority and lack of evidence for improved patient care, asserting that its FDP is widely trusted and used by thousands of NHS staff. Nonetheless, the debate continues, with a bipartisan group of UK politicians warning in June that reliance on a single foreign vendor creates an "unacceptable point of weakness" and advocating for domestic alternatives. A subsequent parliamentary committee echoed these concerns, citing testimony from Greater Manchester. Proponents of the FDP, however, argue that there are no viable alternatives capable of integrating data across the entire NHS, and that breaking the contract could undermine years of progress and negatively impact patient care.
The controversy surrounding Palantir, including comments from co-founder Peter Thiel and CEO Alex Karp, has added a layer of political complexity. Jessica Morley, a health data researcher, noted a potential conflict between Palantir's approach and the NHS's values. MPs involved in recommending the contract termination have cited a "clear mismatch with UK values." Greater Manchester ICB has acknowledged that heightened public concerns have delayed their review of the FDP decision. Critics of the intense scrutiny on Palantir argue that political objections are overshadowing an objective assessment of the FDP's value, with Bartlett warning that triggering the break clause would lead to a regression in data management for many trusts.
